Rebecca Ellston | AMiner学者主页

全面呈现 [Rebecca Ellston] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（55）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 133K,Reduced nuclear PTEN in SCC compared with AC (TMA Set 1).

2023

引用

AI阅读

2Supplementary Table S4 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Kevin Hudson,Urs J. Hancox,Cath Trigwell,Robert McEwen,Urszula M. Polanska,Myria Nikolaou,Pablo Morentin Gutierrez,Alvaro Avivar-Valderas,Oona Delpuech,Phillippa Dudley,Lyndsey Hanson,Rebecca Ellston,

Design and outcome details for each AZD8835 in vivo efficacy study.

2023

引用

AI阅读

3Supplementary Tables 1-3 and Figure 1-7 from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Urs Hancox,Sabina Cosulich,Lyndsey Hanson,Cath Trigwell,Carol Lenaghan,Rebecca Ellston,Hannah Dry,Claire Crafter,Bernard Barlaam,Martina Fitzek,Paul D. Smith,Donald Ogilvie,

Supplementary Tables 1-3 and Figure 1-7. Supp Table 1 Summary of cell line origins and verification. Supp Table 2 Summary of antibodies used in all experimental analysis Supp Fig 1 AZD8186 inhibits PI3K pathway in PTEN null but not PTEN WT PIKC3A MT cells Supp Fig 2 AZD8186 inhibits LPA, EGF and rac dependent Ser473 AKT phosphorylation in serum starved prostate and breast cancer cells Supp Fig 3 Western blot analysis of showing induction of FOXO3a association with the chromatin fraction following treatment with AZD8186 Supp Fig 4 AZD8186 inhibits proliferation in a subset of cancer cell lines Supp Table 3 GI50 of all cell lines showing sensitivity to AZD8186 Supp Fig 5 Western blot protein analysis of PTEN status across a panel of breast and prostate cell lines Supp Fig 6 Pathway biomarker suppression in PC3 and HID28 tumours Supp Fig 7 AZD8186 selectively suppresses pathway biomarkers in tumour versus lung

2023

引用

AI阅读

4Supplementary Table 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 78K, Mutation status of AZ samples acquired through Liverpool Heart and Chest Hospital.

2023

引用

AI阅读

5Supplementary Figure 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 145K, Isoform specificity of PI3Kbeta antibody (AGG4888).

2023

引用

AI阅读

6Supplementary Table 2 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 61K, Clinicopathological features of TMA Set 2.

2023

引用

AI阅读

7Supplementary Figure S6 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Combination of AZD8835 with mTOR kinase inhibitor AZD2014 (+/- fulvestrant) increases anti-tumor efficacy in breast xenografts

2023

引用

AI阅读

8Supplementary Figure S7 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Body Weight time-courses for AZD8835 combination efficacy studies.

2023

引用

AI阅读

9Supplementary Table S2 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Tumor cell line panel composition and growth inhibition sensitivity (GI50) to AZD8835.

2023

引用

AI阅读

10Supplementary Table 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 57K, Clinicopathological features of TMA Set 1.

2023

引用

AI阅读

11Supplementary Figure S5 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

AZD8835 combination with SERDs (fulvestrant or AZD9496) results in tumor regression in mutant PIK3CA, ER+ breast xenografts.

2023

引用

AI阅读

12Supplementary File S1 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Contains Supplementary Material and Methods, Suuplementary Table & Figure Legends and Supplementary References.

2023

引用

AI阅读

13Supplementary Table S3 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Full details on antibodies used in AZD8835 studies.

2023

引用

AI阅读

14Supplementary Materials Text from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Urs Hancox,Sabina Cosulich,Lyndsey Hanson,Cath Trigwell,Carol Lenaghan,Rebecca Ellston,Hannah Dry,Claire Crafter,Bernard Barlaam,Martina Fitzek,Paul D. Smith,Donald Ogilvie,

Supplementary Materials text. Supplementary text to support supplementary data.

2023

引用

AI阅读

15Supplementary File S2 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Details on PK / PD / efficacy modeling in BT474 xenograft model

2023

引用

AI阅读

16Supplementary Figure S4 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Proliferation and mechansitic assays in mutant PIK3CA, ER+ breast cell lines studying combinations of AZD8835 with SERDs, palbociclib or AZD2014.

2023

引用

AI阅读

17Supplementary Figure S1 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Timecourse of PI3K pathway inhibition in MCF7 cells illustrating pathway reactivation over time.

2023

引用

AI阅读

18Supplemental Data Figure Legends from Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors

James T. Lynch,Urszula M. Polanska,Oona Delpuech,Urs Hancox,Antonio G. Trinidad,Filippos Michopoulos,Carol Lenaghan,Robert McEwen, James Bradford,Radek Polanski,Rebecca Ellston,Alvaro Avivar-Valderas,

Supplemental data figure legends

2023

引用

AI阅读

19Supplementary Figure 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 145K, Isoform specificity of PI3Kbeta antibody (AGG4888).

2023

引用

AI阅读

20Supplementary Table 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 57K, Clinicopathological features of TMA Set 1.

2023

引用

AI阅读

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

Cosulich Sabina C合作论文数37

Cumberbatch Marie合作论文数37

Urs Hancox合作论文数31

Ward Lara合作论文数26

Urszula M. Polanska合作论文数25

Hanson Lyndsey合作论文数23

Green Stephen合作论文数22

Francisco Cruzalegui合作论文数22

Trigwell Cath合作论文数Oncology Innovative Medicines, AstraZeneca20

McEwen Robert合作论文数20

Kevin Hudson合作论文数Cancer and Infection Research, AstraZeneca20

Oona Delpuech合作论文数20

Avivar-Valderas Alvaro合作论文数19

Dudley Phillippa合作论文数19

Alys Jones合作论文数16

Gutierrez Pablo Morentin合作论文数16

Paul D. Smith合作论文数15

Myria Nikolaou合作论文数15

Simon Dearden合作论文数Personalised Healthcare and Biomarkers, AstraZeneca12

Sonia Eckersley合作论文数12

Carmen Behrens合作论文数Department of Thoracic Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center;Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center12

Xinying Su合作论文数12

Ignacio I. Wistuba合作论文数Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center;Department of Pathology, The University of Texas MD Anderson Cancer Center12

Neil M. Gray合作论文数12

David P. Blowers合作论文数12

Ximing Tang合作论文数12

Chris Womack合作论文数12

Simon T. Barry合作论文数10

Lenaghan Carol合作论文数8

Barry R Davies合作论文数Medical School, University of Newcastle8

Bernard Barlaam合作论文数Laboratoire de Synthèse Organique Associé au C. N. R. S., Ecole Polytechnique8

Martina Fitzek合作论文数7

Susan E. Critchlow合作论文数6

Staniszewska Anna合作论文数6

Radek Polanski合作论文数4

Hannah Dry合作论文数4

Antonio Garcia-Trinidad合作论文数4

D'Cruz Celina M合作论文数Oncology Innovative Medicines, AstraZeneca4

James Lynch合作论文数4

Powell Steve合作论文数4

Foster Emily合作论文数4

Pilling James E合作论文数4

Klein Stephanie Kristin合作论文数4

Claire Crafter合作论文数4

Filippos Michopoulos合作论文数4

相似学者

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn